Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean‐Jacques Grob, Caroline Robert, Florent Grange et al.|The Lancet Oncology|2015Cited by 264
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineJean‐Jacques Grob, Axel Hauschild, Mayur M. Amonkar et al.|Annals of Oncology|2014Cited by 55
Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal CancerChing-Yu Wang, Xinyue Liu, Changxia Shao et al.|JCO Clinical Cancer Informatics|2023Cited by 2
3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM)Jean‐Jacques Grob, Caroline Robert, Mayur M. Amonkar et al.|European Journal of Cancer|2015Cited by 0